A Multicenter, Prospective, Randomized, Open-label, Phase 4 Trial to Evaluate the Efficacy of Telmisartan/S-Amlodipine(Telminuvo® Tab. 40/2.5mg) on 24-hour Ambulatory BP Control Compared With Telmisartan Monotherapy in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy (TENUVA-BP)

NCT02231788 Phase 4 COMPLETED

The Efficacy of a Fixed Dose Combination of Telmisartan/S-Amlodipine on 24-hour Ambulatory BP Control Compared with Telmisartan Monotherapy

Details

Lead sponsor	Chong Kun Dang Pharmaceutical
Phase	Phase 4
Status	COMPLETED
Enrolment	217
Start date	2014-06
Completion	2018-03

Conditions

• Hypertension

Interventions

• Telminuvo®Tab. 40/2.5mg
• Telmitrend®Tab. 80mg

Primary outcomes

• Change from baseline in the 24hr mean blood pressure by ambulatory blood pressure monitoring(ABPM) at week 8. — Baseline and week 8

Countries

South Korea